Introduction
Although the most common cause of LUTS is BPH, the exact aetiology of BPH causing LUTS is still not completely understood [1] . It has been suggested that hormonal imbalance with epithelial-stromal interaction could be responsible for the development of BPH [2] ; however, the precise mechanism remains uncertain. Sex steroid hormones have been linked to the development of BPH and its associated clinical sequelae [3] . Although androgens may play a role in BPH pathogenesis, the exact mechanism is unclear because their levels decrease as men age [4] . Oestrogens have been recognized as important sex steroids and may play a role in BPH, associated LUTS and bladder complications [4, 5] . ER-a, and subsequently ER-b, have been cloned. Oestrogen acts via these two ligand-activated transcription factors [5] . ER-a and -b genes are located on chromosomes 6 and 14, respectively [6] . These ER subtypes have been shown to be differentially expressed along the lower urinary tract and reproductive system (bladder, urethra, prostate, testes, epididymis, efferent ductules, vas deferens and seminal vesicles) [7] [8] [9] [10] . Differential expression of oestrogen in bladder tissue and its effect on symptoms of benign prostatic enlargement are still not fully elucidated. Although it has been shown in some studies that ER-b is the predominant ER expressed in normal bladder urothelium, it is the ER-a level that increases in the bladder tissue in cases of BOO. There are few data on this, however, and most of these results were from animal studies [7, 8, 11] . It has been suggested that ER-a can have both a pro-and anti-apoptotic action, but the data are conflicting [12] . Although some work has been carried out to determine the ER distribution in prostate tissue and its correlation with LUTS, there is a paucity of data with regard to both the distribution of these ERs in bladder tissue and any correlation with clinical variables in patients with BPH [7] . It is therefore important to understand the relative contribution of ER subtypes to discover new therapies to target ERs and that will be helpful in the management of BPH-LUTS. We hypothesized that ER levels in bladder tissue may be associated with diverse measures of BPH-LUTS. The aim of the present study was to find any association between ER subtypes (ER-a and ER-b) and their differential expression in urinary bladder tissue (epithelial and stromal cells) with various clinical measures of benign prostatic enlargement in patients with BOO.
Material and Methods
After receiving institutional review board approval (1379/MC/ EC/2015), we conducted the present prospective case-control study. Written informed consent was obtained from all the participants. Patients with bothersome LUTS undergoing TURP were included in the case group and age-matched patients undergoing surveillance cystoscopy for evaluation of haematuria, without evidence of BOO, were included in the control group.
Patients who had previously undergone bladder or prostatic surgery, those with catheter drainage, diabetes, neurogenic bladder, active UTI, lower urinary tract malignancy, PSA level >4 ng/mL, use of drugs such as a-blockers, 5-a-reductase inhibitors and phosphodiesterase 5 inhibitors, stricture urethra, bladder calculus and follow-up duration of <1 month were excluded from the study.
All patients underwent detailed evaluation, including a history and physical examination including DRE. In addition to routine investigation, the BPH-related variables IPSS, serum PSA level, prostate volume, peak urinary flow rate (Q max ) and post-void residual urine volume (PVR) were also noted in all patients. Serum testosterone and oestradiol levels were also measured in an early-morning urine sample from all patients.
Cystoscopy was performed as standard in all patients. A minimum of two bladder biopsies were taken~2 cm superolateral to the ureteric orifices in all patients using cold-cup biopsy forceps [13] . After bladder biopsy, standard TURP was also performed in the case group. Bladder biopsy specimens were sent in 10% formalin solution for histopathological examination and immunohistochemistry (IHC) evaluation. Distribution of ER-a and -b in epithelial and stromal cells of the bladder was determined using the IHC technique, as described below, and their correlation with clinical measures of BPH was assessed. Ki 67 was used as a proliferation marker only, and was not correlated with clinical variables. At 1 month postoperatively patients in both groups were assessed according to IPSS, PVR, Q max and prostate volume.
Primary Antibodies
Mouse monoclonal antibodies were used: ER-a antibodies (1:200 dilution; Acris Antibodies, Inc. San Diego, CA, USA) and ER-b antibodies (1:50 dilution; Acris Antibodies), and anti Ki-67 antibodies (clone MB67; Diagnostic BioSystems, Pleasanton, CA, USA).
Immunohistochemical Analysis of Receptors
We carried out IHC analysis in all patients. ER-a, ER-b and Ki 67 mouse monoclonal antibodies were used in pretitrated diluted solutions. All formalin-fixed bladder tissue was embedded in paraffin. These entire tissue samples were incubated with primary antibody (ER-a, ER-b and Ki 67) and final IHC evaluation was carried out. The IHC analyses for all the above markers were performed with the respective antibodies on 4-l thick sections on tissue bondcoated slides using the immunoperoxidase method, as per the manufacturer's instructions. Antigen retrieval was carried out using the heat-induced epitope retrieval method in a Diva Decloaker chamber (Diagnostic Biosystems India, New Delhi, India) using citrate buffer (pH 6.0) after tris buffer wash. Endogenous peroxidase was blocked using hydrogen peroxide solution. Sections were incubated with primary antibody for 1 h 30 min. Biocare's horseradish peroxidase polymer was applied as secondary antibody and 3 0 3 diaminobenzidine as chromogen substrate. Appropriate positive and negative controls were included (Fig. 1A-C) .
The Allred score, as used in breast cancer, was used for semi-quantitative analysis of ERs, including both the proportion score and intensity score [14] . The proportion score ranked positively stained target cells from 0 to 5 as follows: 0 = none; 1 = 1%; 2 = 1-10%; 3 = 10-33%; 4 = 33-66%; and 5 = >66%. The staining intensity score ranged from 0 to 3: 0 = no staining; 1 = weak staining; 2 = intermediate staining; and 3 = strong staining. The two scores were added together and if the final number was ≤2 then this was considered a negative score, while scores >2 were considered positive. At 409 magnification, the areas with highest intensity were identified. Then, also at 4009 magnification, the percentage of ER expression was calculated by counting the number of positive-stained cells in 100 examined cells. A total of five serial sections, comprising both epithelial and stromal tissue, were examined and the mean score (either positive or negative) was calculated for each specimen (ER-a and ER-b in both the epithelium and stromal region). Similarly, for the Ki 67 assay, slides were scanned at 409 magnification to find the maximum positive stained cells and, subsequently, at 4009 magnification, 500 cells each from the epithelium and stroma were assessed. By counting these 1000 random nuclei, a final single Ki 67 score (including both epithelium and stroma) was calculated for each patient.
Statistical analysis was performed using SPSS trial version 20 software. Categorical data were presented as numbers (percent) and were compared using the chi-squared test and odds ratios (95% CIs) were calculated. The quantitative data are presented as mean and SD values and were compared using Student's t-test. Relationships between the quantitative variables were assessed using Pearson's correlation coefficient. P values <0.05 were taken to indicate statistical significance.
Results
In the present series, 53 patients met the inclusion criteria, with 34 patients in the case group and 19 in the control group. Table 1 shows the preoperative clinical characteristics and hormonal profiles for each group, along with statistical analysis. Both groups were age-matched, and serum hormone profile and serum PSA levels were similar in the two groups (P > 0.05). The mean serum testosterone level was 430.62 and 476.79 ng/dL in the case and control group, respectively, while serum oestradiol level did not differ significantly: 40.16 pg/dL in the case group and 35.58 pg/dL in the control group. There were statistically significant differences between the groups with respect to IPSS, PVR, Q max and prostate volume. Table 2 compares the distribution of ER subtypes and Ki 67 (positive staining) between the groups. A positive IHC score (>2) for epithelial ER-a was found in 12 patients in the case group (35.29%) and one patient (5.26%) in the control group, while stromal ER-a was found in 15 patients (44.12%) in the case group and two patients (10.53%) in the control group. Similarly, staining for ER-b in the epithelial and stromal nuclei in the case group showed positive immunoreactivity in 15 (44.12%) and 16 patients (47.06%), respectively, whereas positive immunoreactivity was observed in the epithelial and stromal nuclei in only seven (36.84%) and nine patients (47.37%), respectively, in the control group. Ki 67 expression was present in 32 patients (94.12%) in the case group and 10 (52.63%) in the control group. Thus, we observed heterogeneous expression of these receptors in the two groups, with stronger immunoreactivity of ER-a in the case group than in the control group in both epithelial and stromal nuclei. This finding was not applicable, however, to ER-b, for which epithelial and stromal immunostaining were not significantly different between the case and the control groups. Ki 67 positivity was also more prominent in the case group and the difference was statistically significant. Figure 3 shows the statistically significant difference in IHC scores for epithelial and stromal nuclei of ER-a between the case and the control groups; however, for ER-b, the difference in each staining pattern was not statistically significant.
Pearson's bivariate correlation was used to assess the correlation between various measures of LUTS with receptor status (ER-a and -b; Table 3 ). Epithelial ER-a was significantly positively correlated with IPSS (r = 0.364, P = 0.007), prostate size (r = 0.30, P = 0.029) and PVR (r = 0.587, P = 0.00). Stromal ER-a was also significantly correlated with IPSS (r = 0.508, P = 0.00), prostate volume (r = 0.319, P = 0.020) and PVR (r = 0.580, P = 0.00). Stromal ER-a was also significantly correlated with epithelial ER-a (r = 0.543, P = 0.00); however, epithelial ER-b and stromal ER-b were significantly associated only with an increase in PVR (r = 0.310, P = 0.024 and r = 0.371 and P = 0.006, respectively). Stromal ER-b was also significantly correlated with the other three receptor patterns (epithelial ER-a, stromal ER-a and epithelial ER-b) as shown in Table 3 . Table 4 shows postoperative outcomes after TURP. After TURP, all patients except two successfully voided after catheter removal. In these two patients, ER-a, ER-b and Ki 67 receptor immunoreactivity were all found to be positive. There was significant improvement in postoperative IPSS and Q max , and a decrease from preoperative values in PVR and prostate volume. However, compared with the control group, postoperative outcomes in the case group were inferior with regard to all these clinical variables except for PVR.
Discussion
The steroid hormones oestrogens, progesterone, androgen, glucocorticoids and mineralocorticoids belong to the nuclear transcription factor superfamily. These receptors have many actions, including transcription activation, repression and depression [15, 16] . The actions of oestrogens are mediated through high-affinity receptors that can lead to transcriptional activation after ligand binding. To interpret the role of ERs in bladder tissue, it is necessary to study the distribution of these receptors in human bladder cell lines. The ER has two isoforms: ER-a and ER-b. These isoforms manifest diverse regions of sequence homology [5, 17, 18] . There are conflicting results regarding the location of ERs in the urinary bladder and their ultimate mechanism of action, and most of these results originate from animal studies, so research is still ongong [19] [20] [21] . Initial studies did not observe the presence of ERs at all in the urinary bladder [19] , but later it was recognized that ER-b only is present in the urinary bladder epithelium, with a complete absence of ER-a [20, 21] . Recent studies, however, highlight the presence of both subtypes in urinary bladder cell lines [7, 8, 22, 23] . Rho-associated coiledcoil kinase (ROCK) is a serine/threonine kinase that interacts with RhoA-GTP. This pathway can be activated by several growth factors, integrin, adhesion molecules and other biologically active substances [24] . Overactivity of this pathway in the urinary bladder could be responsible for the occurrence and progression of bladder cancer [25] . It was also assumed that the Rho/ROCK pathway was involved in LUTS [26] and that inhibition of this pathway could lead to improvement in overactive bladder symptoms [27, 28] . Hsu et al. [29] proposed that ER-a modulates the expression of inositol polyphosphate4phosphatase, type II (INPP4B) that will lead to AKT activity and consequently decreased cell growth. They therefore concluded that ER-a has a protective role in bladder cancer initiation and progression [29] . Yeh et al. [30] found that higher ER-a expression in fibroblast modulates chemokine ligand 1 (CCL1) expression interleukin-6 signalling that will lead to bladder cancer invasion. It was also proposed by other researchers that, in response to exogenous oestrogen, ER-a can lead to bladder enlargement in cases of BOO by inhibiting PTEN expression and finally activating the PI3/AKT pathway [7, 8] . Various other studies also confirmed the role of ERs in urothelial cell proliferation [11, 12] ; however, the exact relationship and interaction between ER-a and ER-b are still not completely understood and results are conflicting; while some studies showed that ER-a causes cell proliferation, others found that ER-b is protective against it by repressing the activation of ER-a [31] [32] [33] . ER-b can also lead to significant proliferation of bladder cancer cell lines; however, these observations are still debatable [34] .
To the best of our knowledge, this is first human study to address the distribution of ER subtypes in urinary bladder tissue, using IHC-based semi-quantitative analysis, and their impact on symptoms in patients with BPH. We found that both subtypes of ER were present in the urinary bladder tissue of patients with BPH and in a control group, with variable staining patterns, but it was noted in this study that ER-a was the principle ER subtype that was upregulated in patients with BPH in both epithelial and stromal compartments (35.29% and 44.12%) in comparison to a control group. Nicholson et al. [7] and Lin et al. [8] concluded, in animal studies, that ER-a promotes urothelial cell proliferation and could be a potential target to prevent bladder complications of BPH and showed its correlation with bladder enlargement and urinary retention. Teng et al. [33] observed a higher level of ER-a in normal bladder as well as in bladder cancer tissue proliferation, while there was little change in ER-b level; however, Shen et al. [35] showed that bladder cancer tissue expresses a high level of ER-b, while ER-a levels remain low. A probable explanation for these conflicting findings is the difference in study methodology. In those studies, in contrast to the present human study, these receptors were not categorized by and quantified in different bladder compartments. In the present study, although IPSS and prostate volume were positively correlated with epithelial ER-a and stromal ER-a only, increase in PVR was positively correlated with all four receptor subtypes (epithelial ER-a, stromal ER-a, epithelial ER-b and stromal ER-b). After TURP, the decrease in PVR was significant in the case group compared with the control group. We did not observe any difference postoperatively between the two groups in PVR, although IPSS and prostate volume were still significantly different between the groups. We conclude, therefore, that increase in PVR was not correlated with receptor status. We believe that, although ER-b can lead to changes in urothelial cell lines, these changes were no greater than those found in the control group and it is the ER-a which is responsible for persistent changes, even after removal of obstruction (TURP). Ki 67 levels were higher in the case group than in the control Limitations of the present study include the small number of patients, short follow-up period and lack of post-TURP IHC analysis of receptor status to confirm whether these changes in receptor level revert back to normal level after removal of BPH-related obstruction. Enrolment of a greater number of patients and use of a selective ER modulator against these receptors would enable these findings to be further explored.
In conclusion, the ER subtypes a and b are expressed differentially in the epithelial and stromal compartments of human urinary bladder tissue. ER-a in the epithelial and stromal compartments is a key mediator of oestrogenic action in cases of BOO and was significantly associated with various measures of LUTS in the present study. It may be a potential target for future therapies. 
